{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:29:38Z","timestamp":1760866178863,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.nefro.2019.03.013","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T08:44:47Z","timestamp":1560933887000},"page":"46-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease"],"prefix":"10.1016","volume":"40","author":[{"given":"Ezequiel","family":"Ridruejo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca","family":"Garcia-Agudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Mendizabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Aoufi-Rabih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Fabrizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2019.03.013_bib0105","unstructured":"WHO. Hepatitis C. Fact sheet Number 164. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/"},{"key":"10.1016\/j.nefro.2019.03.013_bib0110","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/liv.13071","article-title":"Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis","volume":"36","author":"Tada","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.nefro.2019.03.013_bib0115","doi-asserted-by":"crossref","first-page":"364","DOI":"10.5604\/01.3001.0011.7382","article-title":"Association between hepatitis C virus and chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Fabrizi","year":"2018","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.nefro.2019.03.013_bib0120","unstructured":"AASLD (American Association for the Study of Liver Diseases) and IDSA (Infectious Disease Society of America): HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. http:\/\/hcvguidelines.org\/ [accessed 21.09.17]."},{"key":"10.1016\/j.nefro.2019.03.013_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40620-017-0446-2","article-title":"Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney","volume":"31","author":"Aoufi-Rabin","year":"2018","journal-title":"J Nephrol"},{"issue":"Suppl. 1","key":"10.1016\/j.nefro.2019.03.013_bib0130","first-page":"S97","article-title":"Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease","volume":"22","author":"Ridruejo","year":"2018","journal-title":"Hemodial Int"},{"key":"10.1016\/j.nefro.2019.03.013_bib0135","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"HCV-TARGET. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.nefro.2019.03.013_bib0140","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3350\/cmh.2016.0087","article-title":"Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function","volume":"23","author":"Shih","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.nefro.2019.03.013_bib0145","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2215\/CJN.02510317","article-title":"Effect of sofosbuvir based hepatitis C virus therapy on kidney function in patients with CKD","volume":"12","author":"Sise","year":"2017","journal-title":"CJASN"},{"key":"10.1016\/j.nefro.2019.03.013_bib0150","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nefro.2019.03.013_bib0155","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"for the STROBE initiative: the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"key":"10.1016\/j.nefro.2019.03.013_bib0160","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-na\u00efve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (The C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.nefro.2019.03.013_bib0165","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy and direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.nefro.2019.03.013_bib0170","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2019.03.013_bib0175","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2015.09.007","article-title":"Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies","volume":"150","author":"Petta","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.nefro.2019.03.013_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2018.10.009","article-title":"Hepatitis C virus and mortality among patients on dialysis: a systematic review and meta-analysis","author":"Fabrizi","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.nefro.2019.03.013_bib0185","first-page":"293","article-title":"Metabolic manifestations and complications associated with chronic hepatitis C virus infection","volume":"12","author":"Wong","year":"2016","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"10.1016\/j.nefro.2019.03.013_bib0190","doi-asserted-by":"crossref","first-page":"612","DOI":"10.4254\/wjh.v10.i9.612","article-title":"Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves haemoglobin A1c","volume":"10","author":"Dong","year":"2018","journal-title":"World J Hepatol"},{"key":"10.1016\/j.nefro.2019.03.013_bib0195","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3748\/wjg.v23.i9.1697","article-title":"Diabetes mellitus, insulin resistance and hepatitis C virus infection: a contemporary review","volume":"23","author":"Desbois","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.nefro.2019.03.013_bib0200","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijcard.2018.04.058","article-title":"Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improve vascular endothelial function","volume":"271","author":"Schmidt","year":"2018","journal-title":"Int J Cardiol"}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519300967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519300967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:54:11Z","timestamp":1759323251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699519300967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0211699519300967"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2019.03.013","relation":{},"ISSN":["0211-6995"],"issn-type":[{"type":"print","value":"0211-6995"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2019.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Nefrolog\u00eda.","name":"copyright","label":"Copyright"}]}}